Clinical TrialJul 21, 2026, 07:03 AM
Pasithea PAS-004 Phase 1 Study Abstract Accepted for ESMO 2026
AI Summary
Pasithea Therapeutics announced that an abstract detailing its Phase 1 dose-escalation study of PAS-004 has been accepted for a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will occur on October 23, 2026, and will cover the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for patients with MAPK pathway-driven advanced solid tumors. The full abstract will be published on the ESMO website, and the company intends to release detailed results concurrently with the presentation.
Key Highlights
- PAS-004 Phase 1 study abstract accepted for poster presentation at ESMO Congress 2026.
- Presentation scheduled for Friday, October 23, 2026, from 15:15–16:00 CEST.
- The study details the safety and pharmacokinetics of PAS-004 in advanced solid tumors.
- PAS-004 is a next-generation macrocyclic oral MEK inhibitor.
- Full abstract will be published on the ESMO Congress website per embargo policy.
- Pasithea plans a follow-up release with detailed results at the time of presentation.
- PAS-004 is currently in Phase 1 trials for advanced cancer and NF1-associated plexiform neurofibromas.
Price Impact
More from KTTA